Skip to content

Effect of omega3 in depression in menopause

Comperssion with the combined effects of omega _3 and citalopram for depression during menopause in postmenopausal women referred to health centers in Hamadan city in 1391: A double-blind clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013052113405N1
Enrollment
84
Registered
2013-07-22
Start date
2013-08-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Depressive episode, Recurrent depressive disorder

Interventions

42 patients will receive 20 mg citalopram with placebo daily for one month
Intervention 1: 42 patients will receive1 gram of omega-3 and 20 mg citalopram daily for one month. Intervention 2: 42 patients will receive 20 mg citalopram with placebo daily for one month.
Treatment - Drugs
Placebo
42 patients will receive1 gram of omega-3 and 20 mg citalopram daily for one month.

Sponsors

Vice-chancellor for Research, Hamadan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
48 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: a) Age range 65-45 years; b) Should last at least 12 months of amenorrhea; c) According to DSM-IV criteria for depression are known to be; d) No history of hysterectomy, oophorectomy with radiation therapy; e) Not taking antidepressant medication and hormone therapy during the last 6 months; f) Not sensitive to herbal drug ; g) Absence of diabetes and cardiovascular disease; h) The Beck score (10-24). Exclusion criteria: a) Drug intolerance; b) Not complete treatment duration; c) The depression scores higher of 24 at follow-up period.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Depression. Timepoint: Before intervention, 1 ,2 ,4 week after intervention. Method of measurement: Beck Questionnaire.

Secondary

MeasureTime frame
Complication of drug. Timepoint: After intervention. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyedeh Zahra Masoumi

Hamedan University of Medical Sciences

zahramid2001@yahoo.comzahra.masoomi@umsha.ac.ir+98 81 1838 0150

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026